NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity. The goal of this program is to improve patient outcomes through understanding of adaptive responses to genome-wide DNA damage in glioblastoma. After hearing and assimilating this program, the clinician will be better able to: 1. Explain evidence showing effectiveness of the CRISPR-Cas9 system for study of DNA damage.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2024-04-11 05:00:00
- End Date: 2024-04-11 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest